Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Mirum Pharmaceuticals Inc has a consensus price target of $54.8 based on the ratings of 15 analysts. The high is $68 issued by JMP Securities on June 18, 2024. The low is $38 issued by Citigroup on May 9, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Evercore ISI Group, and Baird on August 8, 2024, respectively. With an average price target of $56.67 between Cantor Fitzgerald, Evercore ISI Group, and Baird, there's an implied 45.45% upside for Mirum Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Mirum Pharmaceuticals (NASDAQ:MIRM) was reported by Cantor Fitzgerald on August 8, 2024. The analyst firm set a price target for $60.00 expecting MIRM to rise to within 12 months (a possible 54.00% upside). 43 analyst firms have reported ratings in the last year.
The latest analyst rating for Mirum Pharmaceuticals (NASDAQ:MIRM) was provided by Cantor Fitzgerald, and Mirum Pharmaceuticals maintained their overweight rating.
There is no last upgrade for Mirum Pharmaceuticals
There is no last downgrade for Mirum Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mirum Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mirum Pharmaceuticals was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.
While ratings are subjective and will change, the latest Mirum Pharmaceuticals (MIRM) rating was a maintained with a price target of $50.00 to $60.00. The current price Mirum Pharmaceuticals (MIRM) is trading at is $38.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.